Private company

Singular Genomics Systems, Inc.

Singular Genomics Systems, Inc. is an American laboratory analytical instruments company based in San Diego.1

Last updated Oct 20, 2026.

Overview

  • IndustryLaboratory Analytical Instruments1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address3010 Science Park Road, San Diego, Ca 921212
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Our mission is to empower researchers and clinicians to advance science and medicine. The genomic technologies developed over the last two decades, since the first sequencing of the human genome, have greatly improved our understanding of biology, empowered the development of novel therapies and advanced clinical diagnostics. Yet, the potential of genomics is just starting to be realized. Today’s sequencing technologies have made a significant impact, but limitations remain to incorporate these tools into routine clinical practice: long analysis times, labor-intensive protocols, sample-batching requirements and high cost. We are developing powerful, fast, flexible and accurate sequencing products, along with novel applications and sample-to-result workflows, to solve these challenges.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-19.2%Gross margin4
-3531.5%Operating margin4
-3257.3%Net margin4
280.5%Revenue growth, 20234
-53.0%Return on equity4
0.05×Debt to equity4
-$74.6MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue3¢$3.5M
  • Research and development45¢$47.8M
  • Selling, general and admin51¢$54.5M
  • Interest1¢$1.1M

Out of $2.9M in revenue.4 The company lost money this year.

Financial statements

Revenue54$2.9M in 2023
0$1.0M$2.0M$3.0M2021: $0$020212022: $765.0K$765.0K20222023: $2.9M$2.9M2023+281%
Gross profit54-$558.0K in 2023
-$600.0K-$400.0K-$200.0K02021: $0$020212022: -$24.0K-$24.0K20222023: -$558.0K-$558.0K2023+2225%
Operating income654-$102.8M in 2023+273% since 2020
-$150.0M-$100.0M-$50.0M02020: -$27.5M-$27.5M20202021: -$61.3M-$61.3M2021+123%2022: -$93.5M-$93.5M2022+53%2023: -$102.8M-$102.8M2023+10%
Net income654-$94.8M in 2023+239% since 2020
-$100.0M-$75.0M-$50.0M-$25.0M02020: -$27.9M-$27.9M20202021: -$98.8M-$98.8M2021+253%2022: -$90.9M-$90.9M2022−8%2023: -$94.8M-$94.8M2023+4%
Fiscal year20192020202120222023
Revenue$05$765.0K4$2.9M4
Cost of revenue$05$789.0K4$3.5M4
Gross profit$05-$24.0K4-$558.0K4
Research and development$21.2M6$32.7M5$46.2M4$47.8M4
Selling, general and admin$6.3M6$28.6M5$47.3M4$54.5M4
Operating expenses$61.3M5$93.5M4$102.2M4
Operating income-$27.5M6-$61.3M5-$93.5M4-$102.8M4
Interest$718.0K6$846.0K5$763.0K4$1.1M4
Income tax$06$05$04$04
Net income-$27.9M6-$98.8M5-$90.9M4-$94.8M4
Earnings per share-$2.105-$1.284-$1.304
Earnings per share (diluted)-$2.105-$1.284-$1.304
Shares (weighted, basic)47.0M shares571.1M shares472.8M shares4
Shares (weighted, diluted)47.0M shares571.1M shares472.8M shares4

Compare Singular Genomics Systems, Inc. with another company

Corporate structure

Singular Genomics Systems, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Singular Genomics Systems, Inc.

  • ARCH Venture Fund IX, L.P. Filed SCHEDULE 13G/A on Singular Genomics Systems, Inc., latest May 15, 2025 (2 filings since Feb 4, 2022)
  • James E. Flynn Filed SCHEDULE 13D/A on Singular Genomics Systems, Inc., latest Feb 25, 2025 (7 filings since Feb 10, 2023)
  • Domain Partners IX, L.P. Filed SCHEDULE 13G/A on Singular Genomics Systems, Inc., latest Jan 16, 2025 (3 filings since Jan 4, 2022)
  • CRCM LP Filed SC 13D/A on Singular Genomics Systems, Inc., latest Nov 22, 2024 (2 filings since Nov 5, 2024)
  • TANG CAPITAL MANAGEMENT LLC Filed SC 13D on Singular Genomics Systems, Inc., latest Sep 18, 2024
  • Andrew Spaventa Filed SC 13G/A on Singular Genomics Systems, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Eli N. Glezer Filed SC 13G/A on Singular Genomics Systems, Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Revelation Alpine, LLC Filed SC 13G/A on Singular Genomics Systems, Inc., latest Feb 14, 2023 (2 filings since Feb 14, 2022)
  • Singular Genomics Systems, Inc. San Diego, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Singular Genomics Systems, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$21.7M4 Dec 31, 2023$15.3M4 Dec 31, 2022+41.5%
Accumulated depreciation$8.0M4 Dec 31, 2023$4.6M4 Dec 31, 2022+76.0%
Property and equipment, net$13.7M4 Dec 31, 2023$10.8M4 Dec 31, 2022+27.0%
Operating-lease assets (leased space)$57.8M4 Dec 31, 2023$45.9M4 Dec 31, 2022+25.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.2M4 Dec 31, 2023$74.3M4 Dec 31, 2022−78.1%
Marketable securities, current$157.7M4 Dec 31, 2023$170.3M4 Dec 31, 2022−7.4%
Debt securities available for sale$157.7M4 Dec 31, 2023$170.3M4 Dec 31, 2022−7.4%

Inventory

ItemLatestA year beforeChange
Inventory, total$13.6M4 Dec 31, 2023$18.2M4 Dec 31, 2022−25.5%
Raw materials$11.6M4 Dec 31, 2023$14.5M4 Dec 31, 2022−19.9%
Work in process$1.3M4 Dec 31, 2023$3.3M4 Dec 31, 2022−61.1%
Finished goods$669.0K4 Dec 31, 2023$437.0K4 Dec 31, 2022+53.1%

Leadership

Who has led Singular Genomics Systems, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Andrew Spaventa2021–2025

President

  1. David Daly2021–2022

Chief financial officer

  1. Dalen Meeter2023–2025

Chief operating officer

  1. David Daly2021–2022
  2. Jyotsna Ghai2023–2025
2025
Board members and other officers (12)

Timeline

  1. Feb 27, 20258-K Entered a material agreement; Completed an acquisition or sale; New debt or obligation24
  2. Feb 19, 20258-K Shareholder vote25
  3. Feb 13, 20258-K Other events26
  4. Dec 23, 20248-K Entered a material agreement; Other events27
  5. Nov 12, 20248-K Results of operations28
  6. Nov 4, 20248-K Other events29
  7. Sep 19, 20248-K Other events30
  8. Sep 12, 20248-K Other events31
  9. Aug 13, 20248-K Results of operations32
  10. Aug 7, 20248-K Entered a material agreement33
  11. Jul 15, 20248-K Other events34
  12. Jun 27, 20248-K Bylaws or fiscal year changed35
  13. May 26, 2021New chief executive Andrew Spaventa becomes CEO9

Filings

217 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 43 major events, 104 insider forms, 23 large holders, 34 other. The latest 20:

  1. May 15, 2025SCHEDULE 13G/A EDGAR
  2. Feb 27, 20254 EDGAR
  3. Feb 27, 20258-K EDGAR
  4. Feb 25, 2025SCHEDULE 13D/A EDGAR
  5. Feb 25, 20254 EDGAR
  6. Feb 25, 20254 EDGAR
  7. Feb 25, 20254 EDGAR
  8. Feb 25, 20254 EDGAR
  9. Feb 25, 20254 EDGAR
  10. Feb 25, 20254 EDGAR
  11. Feb 25, 20254 EDGAR
  12. Feb 25, 20254 EDGAR
  13. Feb 25, 20254 EDGAR
  14. Feb 25, 20254 EDGAR
  15. Feb 21, 2025EFFECT EDGAR
  16. Feb 21, 2025S-8 POS EDGAR
  17. Feb 21, 2025S-8 POS EDGAR
  18. Feb 21, 2025S-8 POS EDGAR
  19. Feb 21, 2025S-8 POS EDGAR
  20. Feb 21, 2025S-8 POS EDGAR

The 217 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

16 open-market trades by officers, directors and large owners since October 2021: 9 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 14, 2025Spaventa AndrewChief Executive OfficerSale800$19.89$15.9KForm 4
Dec 16, 2024Spaventa AndrewChief Executive OfficerSale180$20.16$3.6KForm 4
Nov 12, 2024Spaventa AndrewChief Executive OfficerSale695$22.55$15.7KForm 4
Sep 18, 2024TANG CAPITAL MANAGEMENT LLC10% ownerBuy32,000$17.21$550.7KForm 4
Sep 17, 2024TANG CAPITAL MANAGEMENT LLC10% ownerBuy40,000$15.33$613.2KForm 4
Sep 16, 2024TANG CAPITAL MANAGEMENT LLC10% ownerBuy50,416$12.74$642.3KForm 4
Sep 15, 2024Spaventa AndrewChief Executive OfficerSale175$12.38$2.2KForm 4
Nov 17, 2023Spaventa AndrewChief Executive OfficerBuy75,000$0.42$31.5KForm 4
Nov 16, 2023Spaventa AndrewChief Executive OfficerBuy43,468$0.41$17.8KForm 4
Nov 16, 2023Glezer Eli N.Chief Scientific OfficerBuy200,000$0.43$86.0KForm 4
Aug 15, 2023Kamdar Kim P.DirectorSale200,000$0.53$106.0KForm 4
Aug 14, 2023Kamdar Kim P.DirectorSale77,991$0.57$44.5KForm 4
Aug 11, 2023Kamdar Kim P.DirectorSale353,657$0.60$212.2KForm 4
May 17, 2023Glezer Eli N.Chief Scientific OfficerBuy170,000$0.82$139.4KForm 4
Dec 12, 2022Glezer Eli N.Chief Scientific OfficerBuy50,000$2.00$100.0KForm 4
May 18, 2022Pellini Michael JDirectorBuy26,834$3.30$88.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Singular Genomics Systems, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSingular Genomics Systems, Inc.1
  • CIK0001850906
  • Employer ID (EIN)81-29484511
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3826 Laboratory Analytical Instruments1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address3010 Science Park Road, San Diego, CA 921211
  • Phone(858) 333-78301
  • Shares outstanding2,511,783 as of Oct 31, 20248
  • Public float$49.0M as of Jun 30, 20234
  • On EDGAR sinceMar 22, 20211
  • Filings264 in all: 4 (102), 8-K (47), 3 (18), 10-Q (11), SC 13G/A (9), DEFA14A (6), SC 13G (6), S-8 (5)1
    All 41 form types

    S-8 POS (5), CORRESP (4), 10-K (3), 144 (3), 5 (3), DEF 14A (3), EFFECT (3), SC 13D (3), UPLOAD (3), ARS (2), S-1/A (2), SC 13D/A (2), SCHEDULE 13D/A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 25-NSE (1), 424B4 (1), 424B5 (1), 8-A12B (1), 8-K/A (1), CERT (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), POS AM (1), PRE 14A (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3 (1), SC TO-I (1), SC TO-I/A (1)

  • Latest filingsAnnual report (10-K) Mar 18, 2024
    Quarterly report (10-Q) Nov 12, 2024
    Proxy statement (DEF 14A) Apr 18, 2024
    Latest 8-K (8-K) Feb 27, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43